Menu
Menu
📣Exciting news! We are thrilled to welcome Argenetics Lab to our global community. The Argentinian company is a leader in genomics testing, offering comprehensive genomic solutions and solving all laboratory processes locally.
The lab will use our comprehensive, end-to-end application to further chronic lymphoma leukemia (CLL) research, allowing Argenetics to enter into the complex field of blood-derived cancers and becoming the first in Argentina to adopt this advanced NGS technology.
“Our interest in Sophia Genetics is founded on their team's unparalleled expertise, technical precision, validation processes, optimized NGS workflow and powerful analytics platforms. We are particularly excited to implement their CLL application to streamline workflows for oncohematologists and support healthcare providers,” said
Gabriela Norese (https://www.linkedin.com/in/gabriela-norese-906308a9/), Medical Director at Argenetics lab (https://www.linkedin.com/company/laboratorio-argenetics/posts/?feedView=all).
This adoption of SOPHiA DDM™ into the Argentinian market has the potential to advance data-driven medicine and provide professionals with an expanded range of testing options to support their work.
"We are honored to work with Argenetics to support the adoption of data-driven medicine into Argentina, helping to bring world-class NGS testing to support healthcare researchers and clinicians who are working to improve outcomes for patients throughout Latin America,” said Ricardo Ramos Mendonca Filho, PhD., Managing Director, LAPAC, SOPHiA GENETICS.
Learn more about our solutions for blood cancers like leukemia here: https://sophiastg.wpenginepowered.com/clinical/oncology/blood-cancers/lymphoid-malignancies/
We’re proud to announce that Bioma Genetics, a leading precision medicine center in Brazil, has expanded its partnership with SOPHiA GENETICS by adopting the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution.
This advanced application enables the accurate identification of HRR gene mutations and genomic instability, providing researchers with comprehensive insights into HRD status.
By integrating this solution, BIOMA GENETICS enhances its capabilities in personalized oncology care, particularly for cancers where HRD is a critical biomarker.
With this expansion, BIOMA GENETICS continues to be part of the growing global network of over 800 institutions leveraging SOPHiA DDM™ to streamline complex variant analysis and strengthen precision medicine across oncology and inherited diseases.
Learn more about our HRD solution: https://lnkd.in/dSY_CAdu
SOPHiA GENETICS is excited to join the ACGH 2025 Congress in Cartagena, Colombia! Meet us at booth #15 to discover the latest innovations of the New Generation SOPHiA DDM™ Platform, with a special focus on Exome advancements. This event is a key milestone for the scientific and academic community, reinforcing Colombia’s leadership in human genetics. Let’s shape the future of genomics together!
Save the date! Sponsored Academic Lunch
June 12th | 1:00-2:00pm | Room 3
Title
From Data to Diagnosis: The Impact of Enhanced Exomes in Precision Medicine
Speakers
En el 2018 una red de colaboradores y especialistas en cáncer en América Latina unió esfuerzos para crear el Consorcio Latinoamericano para el Estudio del Cáncer de Mama y Ovario hereditario (LACAM). El Consorcio LACAM tiene como objetivo reclutar 3,000 casos de múltiples centros en: Argentina, Colombia, Guatemala, México, Paraguay y Perú para desarrollar el estudio de epidemiología genómica más grande de la enfermedad en estas poblaciones.
En este workshop describiremos el origen, composición y objetivos del Consorcio LACAM, sus hallazgos científicos, la eficacia analítica de la tecnología de secuenciación de SOPHiA GENETICS y el enfoque multidisciplinario de la atención al paciente derivado de este esfuerzo de investigación.
Full agenda:
Consorcio Latinoamericano para el estudio del cáncer de mama y ovario hereditario LACAM: un esfuerzo multidisciplinario para la comprensión integral de la epidemiología genómica de la enfermedad
Speaker:
Dr. Felipe Vaca Paniagua, Profesor Investigador
Universidad Nacional Autónoma de México-Instituto Nacional de Cancerología de México
Validación e implementación de una solución personalizada de cáncer hereditario de SOPHiA GENETICS en el Laboratorio Nacional en Salud de la FES-Iztacala UNAM
Speakers:
Dr. Ari Franco Cea, Subject Matter Expert - SOPHiA GENETICS
Dra. Clara Estela Díaz Velásquez, Técnico Académico
FES-Iztacala, Universidad Nacional Autónoma de México
Síndromes de cáncer de mama y ovario hereditario - aspectos clínicos
Speaker:
Dra. Ana Milena Gómez Camacho, Genética Médica
Hospital Universitario San Ignacio
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.